Verhaftet der Albaner Martin Shkreli: Wie dieser Pharma-CEO zum meistgehassten Mann der USA wurde

Für 5 Millionen $ Kaution wurde Artin Shrkeli inzwischen aus der Haft entlassen.

26- Jahren nur in Betrugs Geschäften je im Leben gearbeitet, ein Albanischer Einwanderer in die USA,welcher nun mit seinem Hedge Fund Schlagzeile macht, wo es peinlich ist, das man einem 26 Jährigen hohe Millionen Summen gab, nur für seine Internet Versprechungen. Deutschland ist Opfer der US Finanz Mafia, welche sich die Deutschen Politiker und Pseudo Staatsbanker eingekauft haben.

Martin Shkreli wurde am 17. Dezember 2015 von den Bundesbehörden der USA in Manhattan wegen des Verdachts auf Betrug verhaftet. Nach Angaben der New York Times soll die Verhaftung im Zusammenhang mit einem Rechtsstreit stehen, bei dem ihm vorgeworfen wird, sich als Vorsitzender der Retrophin LLC selbst bereichert zu haben.[9]

Auch Albanische Medien brachten die Story: Martin Shkreli arrested

Shkreli, CEO Reviled for Drug Price Gouging, Arrested on Securities Fraud Charges

32-year-old suspected of plundering Retrophin to pay debts
Martin Shkreli
Photographer: Francesco Nazardo

A boyish drug company entrepreneur, who rocketed to infamy by jacking up the price of a life-saving pill from $13.50 to $750, was arrested by federal agents at his Manhattan home early Thursday morning on securities fraud related to a firm he founded.

Martin Shkreli, 32, ignited a firestorm over drug prices in September and became a symbol of defiant greed. The federal case against him has nothing to do with pharmaceutical costs, however. Prosecutors in Brooklyn charged him with illegally taking stock from Retrophin Inc., a biotechnology firm he started in 2011, and using it to pay off debts from unrelated business dealings. He was later ousted from the company, where he’d been chief executive officer, and sued by its board.

In the case that closely tracks that suit, federal prosecutors accused Shkreli of engaging in a complicated shell game after his defunct hedge fund, MSMB Capital Management, lost millions. He is alleged to have made secret payoffs and set up sham consulting arrangements. A New York lawyer, Evan Greebel, was also arrested early Thursday. He’s accused of conspiring with Shkreli in part of the scheme.

Retrophin replaced him as CEO “because of serious concerns about his conduct,” the company said in a statement. The company, which hasn’t been accused of any wrongdoing, has “fully cooperated with the government investigations into Mr. Shkreli.”

Shkreli’s lawyer didn’t immediately respond to requests for comment. Spokeswomen for Kaye Scholer LLP, where Greebel works, and Brooklyn U.S. Attorney Robert Capers declined to comment. Capers will discuss the case at a press conference Thursday in Brooklyn.

Shkreli’s extraordinary history—and current hold on the public imagination—makes the case more noteworthy than most involving securities fraud. The son of immigrants from Albania and Croatia who worked as janitors and raised him deep in working-class Brooklyn, Shkreli both epitomizes the American dream and sullies it. As a youth, he showed exceptional promise and independence and, after dropping out of an elite Manhattan high school, began his conquest of Wall Street before he was 20.

Turing Pharmaceuticals cat litter
AIDS activists pour cat litter on an image of Shkreli in a makeshift cat litter pan during a protest highlighting pharmaceutical drug pricing, in front of the building that houses Turing’s offices, in New York.
Photographer: Craig Ruttle/AP Photo

His name entered public consciousness after he raised the price more than 55-fold for Daraprim. It is the preferred treatment for a parasitic condition known as toxoplasmosis, which can be deadly for unborn babies and patients with compromised immune systems including those with HIV or cancer. His company, Turing Pharmaceuticals AG, bought the drug, moved it to a closed distribution system and instantly drove the price into the stratosphere.

The moves drew shocked rebukes from Congress, public-interest groups, doctors and presidential candidates, and cast an unwelcome spotlight on the rising prices of older drugs. Donald Trump called Shkreli a “spoiled brat,” and the BBC dubbed him the “most hated man in America.” Bernie Sanders, a Democratic presidential candidate, rejected a $2,700 campaign donation from him, directing it to an HIV clinic. A spokesman said in October that the campaign would not keep money “from this poster boy for drug company greed.”

Shkreli initially responded to the criticism by saying he would lower the Daraprim price and then changed his mind again. When Hillary Clinton tried one more time last month to get him to cut the cost, he dismissed her with the tweet “lol.” At a Forbes summit in New York this month, wearing a hooded sweatshirt, he said if he could have done it over, “I probably would have raised the price higher,” adding, “my investors expect me to maximize profits.”

“The $65 million Retrophin wants from me would not dent me. I feel great. I’m licking my chops over the suits I’m going to file against them”

In fact, it is not only his drug pricing that has turned him into an object of public derision. He recently spent millions on the only copy of a Wu-Tang Clan album that music fans would love to hear and then told Bloomberg Businessweek that he had no immediate plans to listen to it. He spars often on Twitter and message boards, parading his business strategies, musical tastes and politics; he live-streams from his office for long stretches.

And a range of investors has been after him for some time.

Retrophin sued Shkreli in August for misuse of company funds, claiming he engineered numerous transactions between investors in MSMB and the biotechnology firm. Similar allegations are laid out in the company’s regulatory filings.

The company alleged in a complaint filed in Manhattan federal court that, through a disastrous trade with Merrill Lynch in 2011, Shkreli cost MSMB more than $7 million, leaving it virtually bankrupt.

Retrophin also asserts that Shkreli entered into payoff agreements with as many as 10 MSMB investors who lost money when the hedge fund became insolvent. Shkreli paid some investors through fake consulting agreements and others through unauthorized appropriations of stock and cash, the company alleged.

Complex financial maneuvers were used to conceal the payments, Retrophin said. For example, the company accused its former CEO of fraudulently reclassifying a $900,000 equity investment that MSMB made in Retrophin as a loan. He then allegedly had Retrophin pay off that loan to settle another unrelated legal dispute.

The Securities and Exchange Commission, which according to court documents opened an investigation into Shkreli in 2012, is expected to file a parallel civil complaint against him, according to people familiar with the matter.

Shkreli spoke cavalierly of the company’s lawsuit, saying, “The $65 million Retrophin wants from me would not dent me. I feel great. I’m licking my chops over the suits I’m going to file against them.”

Earlier, he had denied wrongdoing in a post on InvestorsHub after Retrophin disclosed it had received a subpoena from federal prosecutors and the preliminary findings from its own investigation of Shkreli. He called the company’s allegations “completely false, untrue at best and defamatory at worst.”

“Every transaction I’ve ever made at Retrophin was done with outside counsel’s blessing,” he said on the investment blog in February, without identifying the lawyers.

Shkreli started his career interning for “Mad Money” host Jim Cramer while still a teenager. After recommending successful trades, Shkreli eventually set up his own hedge fund, quickly developing a reputation for trashing biotechnology stocks in online chatrooms and shorting them, to enormous profit.

Widely admired for his intellect and sharp eye, he pored over medical journals and self-trained in biology. He set up Retrophin to develop drugs and acquire older pharmaceuticals that could be sold for higher profits…..

 

http://www.bloomberg.com/features/2015-martin-shkreli-securities-fraud/

Martin Shkreli Wie dieser Pharma-CEO zum meistgehassten Mann der USA wurde

Verteidigt seine Geschäftspraxis bei Bloomberg: Turing-CEO Martin Shkreli

bloomberg.com
Verteidigt seine Geschäftspraxis bei Bloomberg: Turing-CEO Martin Shkreli

„Aus dem Weg, Walter Palmer. Es gibt einen neuen Anwärter auf den Titel des meistgehassten Mannes des Internets.“

Folgt man dem britischen Independent, so hat ein junger Pharma-CEO aus den USA tatsächlich Walter Palmer, den jagenden Zahnarzt und Schützen des Löwen Cecil, vom Spitzenplatz der Wanted-Liste des Internets verdrängt: Als Verkörperung exorbitant hoher Medikamentenpreise. Auch CNN Money nennt Martin Shkreli den „meistgehassten Mann in Amerika“.

Shkreli, ein ehemaliger Hedgefonds-Manager Anfang 30, hat mit seinem Unternehmen Turing vor kurzem die Rechte an Daraprim gekauft, einem Medikament, mit dem die gefährliche Infektionskrankheit Toxoplasmose behandelt wird. Ende vergangener Woche hat Turing den Preis pro Dosis mehr als verfünfzigfacht – von 13,50 Dollar auf 750 Dollar.

Shkreli hat diese Entscheidung mittlerweile teilweise zurückgenommen. Zuvor hatte er sie allerdings massiv verteidigt: Während er auf Bloomberg TV noch versucht, seine Entscheidung damit zu rechtfertigen, dass Daraprim immer noch günstiger als vergleichbare Produkte sei und die höheren Preise künftige Forschung finanzierten, wird er auf Twitter ausfallend.

Shkreli schießt zurück – mit Eminem

http://www.manager-magazin.de/unternehmen/artikel/wie-martin-shkreli-zum-meistgehassten-mann-der-usa-wurde-a-1054306.html